menu search

MRK / Merck: Solid Pharma Buy With Strong Upside If Keytruda Patents Extended

Merck: Solid Pharma Buy With Strong Upside If Keytruda Patents Extended
Merck has been the best performing Big Pharma stock apart from Eli Lilly over the past 3 years, 1 year, and 3 months. The company drove $59.3bn of revenues in 2022, up >20%. Guidance for FY22 is for $57.7bn - $58.9bn, reflecting falling COVID antiviral sales. Keytruda is Merck's most important asset, the cancer drug driving >40% of revenues in Q1'23. Its patent protection may expire in 2028 although Merck believes they can be extended. Read More
Posted: May 30 2023, 14:03
Author Name: Seeking Alpha
Views: 112353

MRK News  

Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?

By The Motley Fool
October 31, 2023

Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?

Merck and Daiichi Sankyo just signed a multibillion-dollar drug collaboration. The pair will work to develop three medicines to eventually replace Key more_horizontal

BMO Capital upgrades Merck to 'outperform'

By CNBC Television
October 27, 2023

BMO Capital upgrades Merck to 'outperform'

BMO has upgraded Merck to outperform from market perform. more_horizontal

Merck's Profit Beats Estimates on Sales of Its Cancer, COVID-19 Drugs and HPV Shot

By Investopedia
October 26, 2023

Merck's Profit Beats Estimates on Sales of Its Cancer, COVID-19 Drugs and HPV Shot

Merck (MRK) posted better-than-expected results on strong sales of its popular Keytruda cancer drug and HPV vaccine Gardasil, as well as a jump in dem more_horizontal

Merck & Co., Inc. (MRK) Q3 2023 Earnings Call Transcript

By Seeking Alpha
October 26, 2023

Merck & Co., Inc. (MRK) Q3 2023 Earnings Call Transcript

Merck & Co., Inc. (NYSE:MRK ) Q3 2023 Earnings Conference Call October 26, 2023 9:00 AM ET Company Participants Peter Dannenbaum - Vice President, Inv more_horizontal

Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales

By Zacks Investment Research
October 26, 2023

Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales

Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. more_horizontal

Merck (MRK) Q3 Earnings and Revenues Beat Estimates

By Zacks Investment Research
October 26, 2023

Merck (MRK) Q3 Earnings and Revenues Beat Estimates

Merck (MRK) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $1.94 per share. This compares to earnings of more_horizontal

Merck results beat expectations on strong Keytruda, Gardasil and Covid drug growth

By CNBC
October 26, 2023

Merck results beat expectations on strong Keytruda, Gardasil and Covid drug growth

Merck's revenue and earnings beat expectations, and it hiked its sales forecast while lowering its profit outlook. more_horizontal

Merck 3rd-quarter profit tops expectations on COVID pill surprise

By Reuters
October 26, 2023

Merck 3rd-quarter profit tops expectations on COVID pill surprise

Merck & Co on Thursday reported higher-than-expected third-quarter sales and profit on surprisingly strong demand for its COVID-19 treatment, primaril more_horizontal


Search within

Pages Search Results: